PDE5A and pulmonary arterial hypertension: For example, sildenafil, a phosphodiesterase type-5 (PDE-5) inhibitor with vasodilatory properties, commonly used in treatment of pulmonary arterial hypertension (PAH), has been tried in COPD patients who did not have pulmonary hypertension.